ASCO 2022 Conference Coverage


 

Lecture Summary - ASCO 2022 on Perioperative Ramucirumab + FLOT vs. FLOT Alone for Resectable Esophagogastric Adenocarcinoma With High Rate of Signet Cell Component: Final Results of the Multicenter, Randomized Phase II/III Trial

17 views
June 14, 2022
Comments 0
Login to view comments. Click here to Login